• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Transition begins after Pfizer-Pharmacia merger

Article

New York-Pfizer Inc. will invest $400 million to expand its New Jersey facilities and potentially add 1,300 jobs, but plans to close five research and development sites around the world-including two in the United States- and other former Pharmacia Corp. offices as it begins the difficult logistical transition of its $57 billion takeover.

Related Videos
J. Peter Campbell, MD, MPH
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Orbis in-person training takes flight once again
© 2024 MJH Life Sciences

All rights reserved.